, Calif. and
Oct. 3, 2013
/PRNewswire/ -- Amgen (NASDAQ: AMGN) and AstraZeneca (AZN), with its biologics research and development arm MedImmune, today announced the upcoming presentation of several key studies evaluating brodalumab, a human monoclonal antibody targeting the interleukin-17 (IL-17) receptor, for the treatment of moderate to severe psoriasis at the 22
Congress of the European Academy of Dermatology and Venereology (EADV) in
Oct. 2-6, 2013
"The Phase 2 data demonstrate that the primary and secondary end points were met, including many patients achieving and maintaining total skin clearance with continued brodalumab therapy," said
Sean E. Harper
, M.D., executive vice president of Research and Development at Amgen. "We look forward to further investigating brodalumab for patients with moderate to severe psoriasis."
, executive vice president, MedImmune added, "We're very encouraged by these results and the initiation of our Phase 3 program."
, the companies announced the start of the Phase 3 program in moderate to severe psoriasis for brodalumab. The program consists of three Phase 3 studies evaluating treatment with brodalumab compared with ustekinumab and/or placebo.
Abstracts will be presented during the poster session on
Friday, Oct. 4, 2013
Abstracts of Interest Include:
About Brodalumab (AMG 827)
- Maintenance of Clinical Response with Long-Term Brodalumab (AMG 827) Therapy for Psoriasis: Week 96 Results from an Open-Label Extension Study (Poster IST13-0686)
- Difference in Health-Related Quality of Life (HRQoL) with Increased Improvements in Psoriasis Area and Severity Index (PASI) and Maintenance of Skin Clearance (Poster 1030)
- Impact of Treatment with Brodalumab on Psoriasis Symptom Severity: Use of a Novel Patient-Reported Outcome Measure, the Psoriasis Symptom Inventory (PSI) (Poster 1640)
Brodalumab is a highly-selective human monoclonal antibody that binds to and blocks signaling via the interleukin-17 (IL-17) receptor. The IL-17 pathway plays an important role in inducing and promoting inflammatory disease processes. Blocking inflammatory signaling at the IL-17 receptor may be beneficial in the treatment of moderate to severe plaque psoriasis, psoriatic arthritis, and potentially other immune-mediated diseases.